Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
Shots:
- The results from the 1st two cohorts of the P-I/II trial evaluating OCU400 in 18 patients with RP associated with NR2E3 & RRHO mutations and LCA with mutation(s) in the CEP290 gene
- In cohorts 1 & 2 of the trial, 7 patients received a unilateral subretinal inj. of low dose (1.66 x 1010 vg/mL) or medium dose (3.33 x 1010 vg/mL) OCU400 with sev. vision impairment due to RP
- The results from 7 patients showed a stable or improved MLMT score trend in 100%; 71.4% in low & medium dose cohorts experienced ≥1 Lux level improvement in MLMT score vs 28.6% of untreated eyes; 66.7% in cohort 1 at 9mos. follow-up demonstrated a ≥2 Lux level improvement in MLMT score; 8-11 letters of improvement in BCVA score (42.9%), favorable safety profile & visual improvements
Ref: Globe Newswire | Image:Ocugen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
